Condition

Relapsed or Refractory Acute Myeloid Leukemia (AML) (3)

Myelodysplastic Syndromes (1)

Other IDH1-mutated Positive Hematologic Malignancies (1)

Untreated AML (1)

Overall Status

Recruiting (2)

Not yet recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1)

Institut de Recherches Internationales Servier (1)

Tarapeutics Science Inc. (1)

Collaborator

Intervention

ag-120 (1)

hyml-122 (1)

mitoxantrone hydrochloride liposome (1)

Study Documents

Clinical Study Report (1)

Individual Participant Data Set (1)

Informed Consent Form (1)

Statistical Analysis Plan (1)

Study Protocol (1)

Study-level clinical trial data (1)

Intervention Type

drug (3)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

relapsed or refractory acute myeloid leukemia (aml)

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies Trial

Recruiting

Relapsed or Refractory Acute Myeloid Leukemia (AML)
+3 more

AG-120

Birmingham, Alabama
+26 more

Sep 12, 2022

Relapsed or Refractory Acute Myeloid Leukemia (AML) Trial (Mitoxantrone Hydrochloride Liposome)

Not yet recruiting

Relapsed or Refractory Acute Myeloid Leukemia (AML)

Mitoxantrone Hydrochloride Liposome

(no location specified)

Apr 19, 2022

Relapsed or Refractory Acute Myeloid Leukemia (AML) Trial in Suzhou (HYML-122)

Recruiting

Relapsed or Refractory Acute Myeloid Leukemia (AML)

HYML-122

Suzhou, Jiangsu, China

the First Affiliated Hospital of Soochow University

Feb 6, 2022